PARP Inhibitor Market – Increasing approvals of innovative drugs molecules | AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline Plc., Pfizer, Inc

Overview:

PARP inhibitors help in treating disease like cancer, as they inhibit PARP (poly ADP ribose polymerase) enzyme. Various types of cancers are dependent on PARP enzymes, so making these enzymes an effective method for treating cancer. PARP inhibitors can be used for treating subset of ovarian cancer. These inhibitors also assist in restoring DNA damaged due to anti-cancer drugs and UV radiation. The PARP inhibitors block the enzymes which are required for repairing breaks in single strands of the DNA molecule.

Global PARP inhibitor market, was forecast to be valued at US$ 887.7 Mn in 2018, over the forecast period.

Click Here to Get a Sample Copy (Exclusive Offer: UPTO 30% Discount for A Limited Time) @ https://www.coherentmarketinsights.com/insight/request-sample/3037

Drivers:

Rising incidences of cancer is estimated to increase demand for drugs, which is anticipated to fuel growth of the global PARP inhibitor market over the forecast period. For instance, researchers from University of Montreal Hospital Research Centre, have developed a combination therapy for treating ovarian cancer in June 2019.

Furthermore, chemotherapy along with PARP inhibitors can be used for minimizing cancer cells proliferation. Growing R&D activities in cancer treatment sector is estimated to offer productive opportunities to the manufacturers for commercializing new drugs in the PARP inhibitor market.

Breakpoint Therapeutics is a spinoff company formed by Evotec in July 2019, for developing cancer treating drugs, and they raised around US$ 36 Million. These drugs work by blocking the DNA repair mechanism resulting in resisting cancer.

Moreover, growing support from the government for spreading awareness is estimated to boost growth of the global PARP inhibitor market growth during the forecast period. For instance, Australian government declared that they are investing US$ 1.6 Million in Ovarian Cancer Australia. The main aim of the project is to give support and care to the patients suffering from ovarian cancer in Australia. As per the reports by government of Australia, almost 400 individuals with a risk of ovarian cancer can benefit from this project.

Major players are carrying out acquisitions and collaborations for promoting R&D in the ovarian and breast cancer treatment. Clovis Oncology, Inc. initiated a collaboration with Alkermes plc., in February 2019, for Alkerme’s ALKS 4230 investigating interleukin-2 variant immunotherapy along with lucitanib and rucaparib.

Key Takeaways:

• The global PARP inhibitor market is estimated to exhibit a CAGR of 32.4% during the forecast period, due to rising incidences of cancer. The 2018 statistics of World Health Organization mentioned cancer as the second leading reason of death worldwide. It was estimated that around 9.6 million individuals lost their lives to cancer in 2018.
• The Olaparib (Lynparza) segment, among drug types in the global PARP inhibitor market is anticipated to boost growth over the forecast period, due to rising product approvals in emerging and developed countries globally. For instance, Merck and AstraZeneca plc., gained approval from the Health Canada for Lynparza in May 2019. Lynparza is used for maintenance treatment in patients suffering from fallopian tube cancer, peritoneal cancer or BRCA-mutated high-grade epithelial ovarian cancer.
• The ovarian cancer segment, among application, in the global PARP inhibitor market is estimated to drive growth over the forecast period, due to the increased application of PARP inhibitors for the treating ovarian cancer.
• The hospital pharmacies segment, among distribution channel in the global PARP inhibitor market is estimated to augment growth over the forecast period, due to availability of relevant medications at the pharmacies in hospitals.

Key players:

• Key players active in the global PARP Inhibitor market are Ono Pharmaceutical Co., LTD., Merck KGaA, GlaxoSmithKline plc., Jiangsu Hengrui Medicine Co., Ltd, Pfizer, Inc., Karyopharm Therapeutics Inc., AstraZeneca Plc., Sierra Oncology, Inc., AbbVie Inc., Repare Therapeutics Inc., Clovis Oncology Inc., Genentech, Inc. and Bristol – Myers Squibb.

Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/3037

The Study Objectives are:

✔ A comprehensive insight into key players operating in the PARP Inhibitor Market and their corresponding data.
✔ It includes product portfolio, annual revenue, expenditure on research and development, geographical presence, key developments in recent years, and growth strategies.
✔ Regional analysis, which includes insight into the dominant market and corresponding market share.
✔ It also includes various socio-economic factors affecting the evolution of the market in the region.
✔ The report offers a comprehensive insight into different individuals from value chains such as raw materials suppliers, distributors, and stockholders.

Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 PARP Inhibitor Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: PARP Inhibitor Industry Impact

Chapter 2 Global PARP Inhibitor Competition by Types, Applications, and Top Regions and Countries
2.1 Global PARP Inhibitor (Volume and Value) by Type
2.3 Global PARP Inhibitor (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global PARP Inhibitor Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America PARP Inhibitor Market Analysis
Chapter 6 East Asia PARP Inhibitor Market Analysis
Chapter 7 Europe PARP Inhibitor Market Analysis
Chapter 8 South Asia PARP Inhibitor Market Analysis
Chapter 9 Southeast Asia PARP Inhibitor Market Analysis
Chapter 10 Middle East PARP Inhibitor Market Analysis
Chapter 11 Africa PARP Inhibitor Market Analysis
Chapter 12 Oceania PARP Inhibitor Market Analysis
Chapter 13 South America PARP Inhibitor Market Analysis
Chapter 14 Company Profiles and Key Figures in PARP Inhibitor Business
Chapter 15 Global PARP Inhibitor Market Forecast (2022-2028)
Chapter 16 Conclusions
Research Methodology